Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 June 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Chemoembolization followed by liver transplantation for hepatocellular carcinoma

Researchers from Austria find that transarterial chemoembolization, followed by orthotopic liver transplantation, is associated with an excellent outcome in selected patients with hepatocellular carcinoma.

News image

fiogf49gjkf04

Orthotopic liver transplantation (OLT) is the best treatment option for patients with hepatocellular carcinoma (HCC).

However, due to increased waiting times, a proportion of patients are excluded from OLT because of tumor progression. A greater than 20% dropout rate from the waiting list has recently been reported.

In this study, researchers evaluated the effect of preoperative transarterial chemoembolization (TACE) on preventing tumor progression while on a waiting list.

Their results are published in the June issue of Liver Transplantation.

1-, 2-, and 5-year survival rates of 98%, 98%, and 93%, respectively.
Liver Transplantation

Included patients met the selection criteria; solitary lesions ≤ 5 cm, or 3 lesions ≤ 3 cm).

In addition, the team analyzed a separate group of patients with advanced-stage HCC outside the selection criteria, but with at least 50% tumor reduction after TACE.

The researchers identified 48 patients who met the selection criteria

Of these, 7 patients remain on the waiting list, while 41 have undergone OLT.

The team found that the 1-, 2-, and 5-year intention-to-treat survival was 98%, 98%, and 94%, respectively.

In addition, outcome after OLT was also excellent with 1-, 2-, and 5-year survival rates of 98%, 98%, and 93%, respectively.

Furthermore, they found that tumor recurrence occurred in only 1 patient.

The team had also included 15 patients with advanced-stage HCC in this study. However, 3 developed a tumor progression and had to be removed from the list.

They determined that, despite tumor reduction before OLT, these patients had a less favorable outcome in the intention-to-treat analysis and posttransplantation survival.

The researchers found that tumors recurred in 30% of patients after OLT.

Dr Ivo Graziadei's team concluded, "TACE followed by OLT is associated with an excellent outcome in selected patients".

"Furthermore, TACE is highly efficacious in preventing tumor progression while waiting for OLT".

"Although TACE reduced tumor preoperatively, it failed to show a beneficial effect on patient survival in advanced-stage HCCs".

Liver Transpl 2003; 9: 557-63
04 June 2003

Go to top of page Email this page Email this page to a colleague

 31 May 2018 
Diagnostic for NAFLD  
 31 May 2018 
Bile acids and the risks for hepatotoxicity
 31 May 2018 
Rectal cancer female sexuality score
 30 May 2018 
Fungal dysbiosis in cirrhosis
 30 May 2018 
Placebo rates in ulcerative colitis trials
 30 May 2018 
Follow-up testing and colorectal cancer mortality
 29 May 2018 
Organ transplantation donors
 29 May 2018 
Novel therapies for IBD
 29 May 2018 
Helicobacter pylori infection to stomach cancer
 28 May 2018 
Mesalazine in ulcerative colitis
 28 May 2018 
Technology and management of digestive diseases
 28 May 2018 
Therapeutic strategies for HCV
 25 May 2018 
Post‐operative complications in elderly IBD
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Colorectal cancer–specific mortality
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Chronic Hep B
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Symptom assessment in cirrhotic ascites
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
European guidelines on pancreatic cystic neoplasms

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us